首页> 外文期刊>Human Pathology >Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years.
【24h】

Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years.

机译:世界卫生组织评估的有丝分裂活动指数和有丝分裂印象通过快速扫描对55岁以下的浸润性导管癌患者的预后差异。

获取原文
获取原文并翻译 | 示例
       

摘要

The proliferation marker mitotic activity index is the strongest prognostic indicator in lymph node-negative breast cancer. The World Health Organization (WHO) 2003-defined procedure for determining WHO-mitotic activity index is often replaced by a quick scan mitotic impression. We evaluated the prognostic consequences of this practice in 433 T(1-3)N(0)M(0) lymph node-negative invasive ductal type breast cancers with long-term follow-up (median, 112 months; range, 12-187 months). Twenty-seven percent of the studied cases developed distant metastases, and 25% died of disease. Agreement between WHO-mitotic activity index (0-5 = 1, 6-10 = 2, >10 = 3) and mitotic impression (1, 2, 3) categories was 66% (kappa = 0.41), including 85% for category 1, 26% for category 2, and 52% for category 3. The WHO-mitotic activity index was a much stronger prognosticator than the mitotic impression, and the 10-year survival rates of the same categories (eg, mitotic activity index and mitotic impression category both 2) differed greatly. When grade was assessed by combining WHO-mitotic activity index or mitotic impression with the same values for tubular formation and nuclear atypia, grades disagreed in 18% of the cases. Deviation from the formal WHO-mitotic activity index assessment guidelines in breast cancer often results in erroneous prognosis estimations with therapeutic consequences and may explain why the prognostic value of proliferative activity in breast cancer is not always confirmed.
机译:增殖标志物的有丝分裂活性指数是淋巴结阴性乳腺癌中最强的预后指标。世界卫生组织(WHO)2003年定义的确定WHO有丝分裂活动指数的程序通常被快速扫描有丝分裂印象所代替。我们评估了这种做法在433 T(1-3)N(0)M(0)淋巴结阴性浸润性导管型乳腺癌中的长期预后(中位数,112个月;范围,12- 187个月)。研究病例中有27%发生远处转移,而25%死于疾病。 WHO有丝分裂活动指数(0-5 = 1、6-10 = 2,> 10 = 3)和有丝分裂印象(1、2、3)类别之间的一致性为66%(kappa = 0.41),包括类别的85% 1,类别2为26%,类别3为52%。WHO有丝分裂活动指数比有丝分裂印象和相同类别的10年生存率(例如有丝分裂活动指数和有丝分裂)的预后要强得多。印象类别2)都相差很大。当通过将WHO有丝分裂活动指数或有丝分裂印象与相同的肾小管形成和核非典型性值相结合来评估等级时,在18%的病例中等级不一致。偏离正式的WHO有丝分裂活性指数评估指南通常会导致错误的预后估计,并产生治疗性后果,并且可能解释了为什么并不总是能证实增殖活性在乳腺癌中的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号